% | $
Quotes you view appear here for quick access.

Sequenom Inc. Message Board

  • busy26795 busy26795 Aug 5, 2013 7:18 AM Flag

    SQNM Sequenom CMM's MaterniT21 PLUS testing service received clinical laboratory permit from New York State

    SQNM Sequenom CMM's MaterniT21 PLUS testing service received clinical laboratory permit from New York State

    Co announced that the New York Department of Health's Wadsworth Center Clinical Laboratory Evaluation Program (CLEP) has issued a clinical laboratory permit to allow the Sequenom Center for Molecular Medicine's San Diego facility to provide its noninvasive prenatal laboratory-developed test, the MaterniT21 PLUS test, to healthcare professionals in the state of New York, effective August 1, 2013. In addition, Sequenom CMM's CLIA laboratory location in North Carolina has received accreditation by the College of American Pathologists, indicating that it has met all applicable standards required by the organization to provide quality laboratory services. At this time, Sequenom CMM offers bicoastal laboratory testing services to healthcare professionals, as all three laboratory sites located in California, Michigan and North Carolina are CLIA-certified and CAP-accredited, demonstrating they meet the highest quality and safety standards for laboratory testing.

    Under Creative Commons License: Attribution

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • so we didn't have it last year?

    • CEO doesn't do a press release or warning on the codes impacting earnings or any other material news this year and a permit from NYS is major news? Nonsense!
      amajer2002 • May 17, 2013 12:36 PM
      CEO Withheld Material Information During the Last Q1 While Stock Dropped 40%
      Sequenom’s CEO committed investor fraud by his premeditated acts of not honestly promoting the company iincluding;
      -by his withholding of material information, not issuing warranted press releases, during the first quarter on the signing of the BCBS contract covering up to 100 million lives;
      -failure to disclose positive coverage decision, in a press release or otherwise, by all the major insurance companies to cover their key test;
      -the CEO not issuing a Press Release on the publishing of a large patient study on RetnaGene to diagnosis AMD a key product to Sequenoms future;
      -his issuing of a lack luster cystic fibrosis Press Release, by design, on major test enhancements providing 6 times greater findings than any other test in the market;
      -by not disclosing significant developments where the U.S. Patent Office declared several Patent Interference Proceedings;
      -without giving a reason the CEO suddenly stopped disclosing monthly tests in the first quarter while the stock price is dropping 40%;
      -his setting absurdly low company goals which he knew to be untruthful to financial benefit himself and other directors;
      -by the CEO underreporting the truthful financial status (material information) of the company to shareholders;
      -his failing to honestly promote its pipeline for questionable reasons
      -by his not discussing the reason for the expansion of laboratory space;
      -for the CEO and BOD’s failure to exercise any fiduciary responsibilities of protecting all shareholders from stock price manipulation
      The truthful release of any of the above significant material information would have protected and likely increased shareholder value during the last quarter preventing a 40 percent stock los

    • A sane person on the board. That's refreshing. Thank you

      Sentiment: Strong Buy

1.13-0.06(-5.04%)Jun 24 4:00 PMEDT